Other targets of interest include the PSCA (NCT05732948 and NCT05805371) and kallikrein 2 (KLK2) (NCT05022849), both of which display high expression in prostate cancer (Table 4) [125,126,127,128,129]. This evidence concerns the gene KLK2 and prostate carcinoma.